Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: Week 144 results from a real-world, multicentre cohort study

Ogawa, E; Nakamuta, M; Koyanagi, T; Ooho, A; Furusyo, N; Kajiwara, E; Dohmen, K; Kawano, A; Satoh, T; Takahashi, K; Azuma, K; Yamashita, N; Yamashita, N; Sugimoto, R; Amagase, H; Kuniyoshi, M; Ichiki, Y; Morita, C; Kato, M; Shimoda, S; Nomura, H; Hayashi, J

Ogawa, E (通讯作者)，Kyushu Univ Hosp, Dept Gen Internal Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022; 56 (4): 713

Abstract

Background Tenofovir alafenamide (TAF) may be preferable to other nucleos(t)ide analogues (NA) regarding outcomes against chronic hepatitis B virus (H......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索